Patents Assigned to Transgene S.A.
  • RECOMBINANT VIRAL VACCINE
    Publication number: 20100129403
    Abstract: The present invention concerns new recombinant viral vaccines. In particular the present invention provides combination products that comprise recombinant viral vectors and specific compounds able to improve the immune response raised in vivo by said recombinant viral vectors.
    Type: Application
    Filed: June 15, 2007
    Publication date: May 27, 2010
    Applicant: Transgene S.A.
    Inventors: Jean-Yves Bonnefoy, Stephane Paul
  • Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
    Patent number: 7695960
    Abstract: The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.
    Type: Grant
    Filed: March 21, 2007
    Date of Patent: April 13, 2010
    Assignees: Transgene S.A., Institut National de la Sante et de Recherche Medicale
    Inventors: Geneviève Inchauspe, Anne Fournillier, Jean-Daniel Abraham, Maria Dimitrova-Tchomakov, Marie Parnot
  • Multifunctional Cytokines
    Publication number: 20100074869
    Abstract: The present invention relates to a novel fusion protein with the formula X-Y, or Y-X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.
    Type: Application
    Filed: September 15, 2009
    Publication date: March 25, 2010
    Applicant: Transgene, S.A.
    Inventor: Stephane Paul
  • HPV-16-BASED PAPILLOMAVIRUS VACCINES
    Publication number: 20100061957
    Abstract: Compositions containing one or more early polypeptide(s) of human papillomavirus (HPV)-16 or a nucleic acid encoding one or more early polypeptide(s) of HPV-16 are useful for preventing or treating an infection or a pathological condition caused by at least one papillomavirus other than HPV-16; the subject compositions are of very special interest in immunotherapy, in particular for preventing or treating HPV persistent infections that might promote cervical intraepithelial neoplasia (CIN) and ultimately cervical cancer.
    Type: Application
    Filed: April 17, 2007
    Publication date: March 11, 2010
    Applicant: Transgene S.A.
    Inventors: Ronald Rooke, Stéphane Paul
  • HPV-18-BASED PAPILLOMAVIRUS VACCINES
    Publication number: 20100055069
    Abstract: Compositions containing one or more early polypeptide(s) of human papillomavirus (HPV)-18 or a nucleic acid encoding one or more early polypeptide(s) of HPV-18 are useful for preventing or treating an infection or a pathological condition caused by at least one papillomavirus other than HPV-18; the subject compositions are of very special interest in immunotherapy, in particular for preventing or treating HPV persistent infections that might promote cervical intraepithelial neoplasia (CIN) and ultimately cervical cancer.
    Type: Application
    Filed: April 17, 2007
    Publication date: March 4, 2010
    Applicant: TRANSGENE S.A.
    Inventors: Ronald Rooke, Stéphane Paul
  • Pharmaceutical compositions for treating papillomavirus tumors and infection
    Patent number: 7670607
    Abstract: A pharmaceutical composition for treating or preventing a papillomavirus infection or tumor, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: March 2, 2010
    Assignee: Transgene S.A.
    Inventors: Jean-Marc Balloul, Nadine Bizouarne, Marie-Paule Kieny
  • COMPOSITION COMPRISING THE POLYPROTEIN NS3/NS4 AND THE POLYPEPTIDE NS5B OF HCV, EXPRESSION VECTORS INCLUDING THE CORRESPONDING NUCLEIC SEQUENCES AND THEIR THERAPEUTIC USE
    Publication number: 20100008941
    Abstract: The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.
    Type: Application
    Filed: May 26, 2009
    Publication date: January 14, 2010
    Applicants: TRANSGENE S.A., INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Anne Fournillier, Genevieve Inchauspe, Jean-Daniel Abraham, Maria Dimitrova-Tchomakov, Marie Parnot
  • USE OF PPD FOR THE ADJUVANTATION OF A NUCLEIC ACID VACCINE
    Publication number: 20090317422
    Abstract: The present invention provides a novel adjuvant for nucleic acid vaccines, and in particular the present invention provides nucleic acid vaccines that comprise, or are administered in association with PPD. The present invention also provides methods to improve the therapeutic efficacy of nucleic acid vaccines.
    Type: Application
    Filed: June 14, 2007
    Publication date: December 24, 2009
    Applicant: TRANSGENE S.A.
    Inventors: Jean-Yves Bonnefoy, Jean-Marc Limacher, Stéphane Paul
  • Multifunctional cytokines
    Patent number: 7608267
    Abstract: The present invention relates to a novel fusion protein with the formula X—Y, or Y—X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X; it also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule; it also relates to infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles; is also relates to a method for recombinantly producing such a fusion protein; and, lastly, it also relates to a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: October 27, 2009
    Assignee: Transgene S.A.
    Inventor: Stéphane Paul
  • Mutant having uracil phosphoribosyl transferase activity
    Patent number: 7572438
    Abstract: The invention concerns a polypeptide having a uracil phosphoribosyl transferase (UPRTase) by mutation of one or several residues of the UPRTase. The invention also concerns a nucleotide sequence coding for the UPRTase mutant, a vector for expressing the latter, a viral particle, a host cell, and a composition containing them. The invention further concerns their therapeutic use and a treatment method using them. The invention is particularly useful in the context of therapy by suicide genes, in particular, for treating proliferative and infectious diseases.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: August 11, 2009
    Assignee: Transgene S.A.
    Inventors: Philippe Erbs, Richard Jund
  • Hepatitis C Virus Non Structural Fusion Protein
    Publication number: 20090186046
    Abstract: The present invention relates to an isolated fusion protein comprising at least three NS polypeptides originating from a hepatitis C virus which are configured in said fusion protein in an order which is distinct of the order in which they appear in the native configuration. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector. The present invention also relates to a method for recombinantly producing such a fusion protein.
    Type: Application
    Filed: March 6, 2007
    Publication date: July 23, 2009
    Applicant: TRANSGENE S.A.
    Inventors: Ann Fournillier, Genevieve Inchauspe, Laurence Chatel, Francois Penin
  • Modified adenovirus fibre and uses
    Patent number: 7560527
    Abstract: The invention concerns an adenovirus fiber modified by mutation of one or several residues of the region included between residues 491 and 505 of SEQ ID NO: 1, the viral particles or pseudo-particles comprising such a fiber and their uses.
    Type: Grant
    Filed: November 23, 2000
    Date of Patent: July 14, 2009
    Assignee: Transgene S.A.
    Inventors: Valérie Legrand, Philippe Leissner
  • Kit of parts designed for implementing an antitumoral or antiviral treatment in a mammal
    Publication number: 20090170795
    Abstract: The present invention relates to a kit of parts comprising a nucleic acid sequence encoding a permease and a drug comprising one nucleobase moiety or a precursor thereof. The present invention further relates to a kit of parts comprising a precursor of a drug comprising a gene coding a permease and a nucleic acid sequence comprising a suicide gene. The present invention also relates to a vector comprising a gene coding a permease and a suicide gene.
    Type: Application
    Filed: October 26, 2005
    Publication date: July 2, 2009
    Applicant: TRANSGENE S.A.
    Inventor: Philippe Erbs
  • Multifunctional cytokines
    Patent number: 7534585
    Abstract: The present invention relates to a novel fusion protein with the formula X—Y, or Y—X, wherein X represents a first immunoregulating polypeptide and Y represents a second immunoregulating polypeptide different from X. The present invention also relates to a nucleic acid molecule encoding such a fusion protein and a vector comprising such a nucleic acid molecule. The present invention also provides infectious viral particles and host cells comprising such a nucleic acid molecule or such a vector as well as a process for producing such infectious viral particles. The present invention also relates to a method for recombinantly producing such a fusion protein. Finally, the present invention also provides a pharmaceutical composition comprising such a fusion protein, a nucleic acid molecule, a vector, infectious viral particles and a host cell as well as the therapeutic use thereof.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: May 19, 2009
    Assignee: Transgene S.A.
    Inventor: Stephane Paul
  • PHARMACEUTICAL COMPOSITIONS FOR TREATING PAPILLOMAVIRUS TUMORS AND INFECTION
    Publication number: 20090104156
    Abstract: A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.
    Type: Application
    Filed: December 8, 2008
    Publication date: April 23, 2009
    Applicant: Transgene S.A.
    Inventors: Jean-Marc Balloul, Nadine Bizouarne, Marie-Paule Kieny
  • Pharmaceutical compositions for treating papillomavirus tumors and infection
    Patent number: 7488482
    Abstract: A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined-with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: February 10, 2009
    Assignee: Transgene S.A.
    Inventors: Jean-Marc Balloul, Nadine Bizouarne, Marie-Paule Kieny
  • Chimeric promoters for controlling expression in smooth muscle cells
    Patent number: 7482155
    Abstract: The present invention concerns a chimeric construct comprising a SMC-specific promoter operably linked to a muscle-specific enhancer. It also provides an expression cassette comprising such a chimeric construct to control expression of a therapeutic gene. Finally, the invention relates to a recombinant vector, a viral particle, an eukaryotic host cell, a composition comprising said expression cassette and their use for specific expression in SMCs and for therapeutic or prophylactic purposes, a method for the treatment of a human or animal organism as well as a transgenic non-human animal comprising integrated into its genome the chimeric construct, the expression cassette or the vector of the present invention.
    Type: Grant
    Filed: July 4, 2001
    Date of Patent: January 27, 2009
    Assignee: Transgene S.A.
    Inventors: Sébastien Ribault, Pascal Neuville, Majid Mehtali
  • METHOD OF IDENTIFYING A MHC CLASS I RESTRICTED T CELL RESPONSE
    Publication number: 20080227082
    Abstract: Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides and polypeptides and therapeutic uses thereof. Moreover, indications for selecting appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA-type of the patient to be treated or tested are described.
    Type: Application
    Filed: March 4, 2008
    Publication date: September 18, 2008
    Applicants: Transgene S.A., Imperial Cancer Research Technology, Ltd.
    Inventors: Joyce TAYLOR-PAPADIMITRIOU, Lukas Carl Heukamp, Rienk Offringa, Cornelis Johanna Maria Melief, Bruce Acres, Mireille Thomas
  • Method of inactivating enveloped viruses in a viral preparation of non-enveloped viruses
    Patent number: 7378265
    Abstract: The present invention relates to a method of inactivating enveloped viruses in a viral preparation predominantly containing non-enveloped viruses by the action of a solvent at a temperature of between ?5° C. and +50° C. and at a pH of between about 5 and 9. Its subject is also a method of preparing a viral preparation comprising such a method of inactivation. The invention also relates to a viral preparation obtained according to the method of the invention. Finally, it relates to a host cell and a composition comprising such a viral preparation as well as their uses for therapeutic or prophylactic purposes.
    Type: Grant
    Filed: December 12, 2005
    Date of Patent: May 27, 2008
    Assignee: Transgene S.A.
    Inventors: David Gaillac, Michel Koehl
  • Poxvirus with targeted infection specificity
    Patent number: 7354591
    Abstract: The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: April 8, 2008
    Assignee: Transgene S.A.
    Inventors: Jean-Marc Balloul, Stéphane Paul, Michel Geist
  • Process for the preparation of ketoximes
    Patent number: 5117060
    Abstract: Disclosed is an improved process for the preparation of ketoximes, especially ketoximes derived from branched chain ketones, wherein a ketone is reacted with a hydroxylamine salt in the presence of an alkanol, a heterogeneous base and up to about 5 weight percent, based on the weight of the ketone and alkanol, water.
    Type: Grant
    Filed: June 10, 1991
    Date of Patent: May 26, 1992
    Assignee: Eastman Kodak Company
    Inventor: Jonathan S. Witzeman